A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2015

At a glance

  • Drugs INCB 47986 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 03 Feb 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 12 Aug 2014 According to ClinicalTrials.gov, study inclusion/exclusion criteria updated to include Group 2 patients. Accordingly, planned number of patients changed from 60 to 100.
    • 12 Aug 2014 Planned number of patients changed from 60 to 100 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top